



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/582,978	06/15/2006	Morten Bryhn		8212

22852 7590 05/24/2011  
FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER  
LLP  
901 NEW YORK AVENUE, NW  
WASHINGTON, DC 20001-4413

EXAMINER
----------

BETTON, TIMOTHY E

ART UNIT	PAPER NUMBER
----------	--------------

1627

MAIL DATE	DELIVERY MODE
-----------	---------------

05/24/2011

PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

# Office Action Summary

**Application No.**

10/582,978

**Applicant(s)**

BRYHN ET AL.

**Examiner**

TIMOTHY BETTON

**Art Unit**

1627

**-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --**  
**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 09 May 2011.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 13, 15-22, 37, 39-46, 49-55, 57, 58, 60 and 61 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 13, 15-22, 37, 39-46, 49-55, 57, 58, 60 and 61 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/SB/08)  
Paper No(s)/Mail Date \_\_\_\_\_
- 4) ☐ Interview Summary (PTO-413)  
Paper No(s)/Mail Date: \_\_\_\_\_
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: \_\_\_\_\_

## **DETAILED ACTION**

### ***Continued Examination Under 37 CFR 1.114***

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 9 May 2011 has been entered.

Applicants set of Remarks filed on 9 May 2011 have been acknowledged and duly made of record.

### ***Response to Arguments***

Applicants' argue that Breivik and Corkey fail to establish a *prima facie* case of obviousness. Applicants submit that Breivik and Corkey, alone or in combination, fail to teach or suggest each and every element of the claimed invention. Also, Applicants submit that Breivik and Corkey, alone or in combination, would fail to motivate one skilled in the art to modify the composition to arrive at the presently pending claims.

As the Office stated in the Office Action, Breivik teaches that the composition comprises at least 80% omega-3 polyunsaturated fatty acids and least 75% of the total fatty acids comprise EPA and DHA. Office Action at 5. In contrast, the pending claims recite an upper limit of EPA and DHA of 70 %. Thus, the claimed range falls outside of the range disclosed in Breivik and it does not offer any suggestion or motivation regarding the claimed range.

*Corkey does not cure the deficiency of Breivik since it does not teach or suggest the claimed concentrations of EPA and DHA or that the concentration of DHA is greater than the concentration of EPA. Instead, Corkey teaches "a small portion of EPA and DHA" as pointed out by the Office in the final Office Action on page 7.*

Applicants' arguments are considered but are not found persuasive in as far as claims 13, 37, and 49 disclose limitations that do not reasonably preclude a 1:1 ratio of EPA: DHA. It is also duly noted that independent claim 13 discloses the limitation EPA: DHA which reasonably encompasses a 1:1 ratio of EPA: DHA.

Claims 54-55 and 57-61 disclose exact concentrations for EPA in comparison to DHA.

Applicants' arguments are considered and are found persuasive in as far as the reference employed in the previous action does not fairly teach the limitations of claims 54-55, 57-58, and 60-61 drawn to increasing the amount of DHA and EPA by 3 times in view of the synergistic effects in Corkey by using "a small amount".

Further, applicants assert [that] Breivik and Corkey, alone or in combination, fail to teach or suggest each and every element of the claimed invention. Also, Applicants submit that Breivik and Corkey, alone or in combination, would fail to motivate one skilled in the art to modify the composition to arrive at the claimed inventions. This results in the lack of a *prima facie* case of obviousness. Applicants respectfully request the withdrawal of the rejection.

Applicants' arguments are considered but are not found persuasive because the ratios according to Breivik and Corkey could be extrapolated and reasonably optimized via due experimentation. Motivation to increase the ratio of DHA to EPA is drawn to each component

Art Unit: 1627

(taken separately), which individually treat the effects of *inter alia* obesity. Increasing one component over another (variably) would be due experimentation.

Applicant's arguments, see page 10 in the first full paragraph, filed 9 May 2011, with respect to the rejection(s) of claim(s) 54-55, 57-58, and 60-61 under Breivik and Corkey et al. have been fully considered and are persuasive. Therefore, the rejection has been withdrawn. However, upon further consideration, a new ground(s) of rejection is made in view of O'Connor et al (USPN 6,596,302 B2).

### ***Status of the Claims***

Claims 13, 15-22, 37, 39-46, 49-55, 57-58, and 60-61 are pending further prosecution on the merits.

### ***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.

Art Unit: 1627

3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 13, 15-22, 37, 39-46, 49-55, 57-58, and 60-61 are rejected under 35 U.S.C. 103(a) as being unpatentable over O'Connor et al. (USPN6,596,302 B2) and Breivik et al. (USPN 5,502,077) in view of Corkey et al.

O'Connor et al. teach in column 19 at line 16 a DHA: EPA ratio preferably at least 3:1.

O'Connor et al. teach in the instant abstract [m]ethods for providing nutrition and for enhancing neurological development of preterm infants are disclosed. Also disclosed is an improved nutritional composition containing specified amounts of DHA and AA as well as their precursor essential fatty acids alpha-linolenic and linoleic acids. The methods involve feeding LCP supplemented, nutrient-enriched formulas for an extended feeding regimen, typically until at least 3 months corrected age (CA), preferably to 6 or even 12 months CA. The neurological developments, for example, visual development, motor development and language development were enhanced without findings of anthropometric growth faltering or inhibition. Thus, based upon the current abstract, the limitations of claim 13 are also hereby encompassed as the one of

skill would reasonably expect formulations for infants containing DHA:EPA to control the obesity (fat content) of infants.

Breivik et al. teach a fatty acid composition comprising at least 80% by weight of omega-3-fatty acids, salts or derivatives thereof, wherein (all-Z)-5,8,11,14,17-eicosapentaenoic acid (EPA) and (all-Z)-4,7,10,13,16,19-docosahexaenoic acid comprises at least 75% by weight of the total fatty acids. The compositions can be used for the *treatment* [...] of multiple risk factors for cardiovascular diseases (abstract only).

Breivik et al. teach that present invention relates to a fatty acid composition comprising at least 80% by weight of omega-3 polyunsaturated fatty acids, wherein at least 75% by weight of the total fatty acids comprise omega-3 (all-Z)-5,8,11,14,17-eicosapentaenoic acid (EPA) C 20:5 and (all-Z)-4,7,10,13,16,19-docosahexaenoic acid (DHA) C 22:6 9column 1, lines 5-10).

Breivik et al. teach the same and exact preferred ratio limitation in the instant claims. The upgrading of the EPA fraction to obtain a weight ratio of EPA: DHA of from 1:1 to 2:1, especially 3:2 or the upgrading of the DHA fraction to obtain an EPA: DHA weight ratio of from 1:1 to 1:2 may be achieved in the molecular distillation stage. The method also provides the possibility of using supercritical fluid extraction and/or chromatography in the second stage with CO.sub.2 eventually containing a more polar modifier, such as ethanol, in order to concentrate the EPA and/or DHA fraction (column 3, lines 61-67; column 4, lines 1 and 2).

Breivik et al. teach fish oil which is of animal origin (column 1, line 38). This limitation of oil also anticipates the limitation in the claims drawn to a liquid form (claim 51).

Breivik further renders obvious the claimed invention by teaching that this preferred ratio of EPA: DHA has an advantageous effect on risk factors for cardiovascular diseases (column 2, lines 50-67).

Breivik et al. teaches an esterified formulation comprising EPA: DHA (column 3, lines 2-39).

Breivik et al. does not go into specific detail as to risks of cardiovascular disease in view of the specific treatment thereof.

However, Corkey et al. essentially teach dietary products for infant child and adult nutrition which possess adequate levels and **ratios of medium chain fatty acids and .omega.-polyunsaturated fatty acids.** Consumption of these dietary products can contribute to the prevention of obesity in developing individuals and can contribute to a **reduction in body fat mass in individuals who are trying to loose weight or reduce body fat mass (e.g., obese individuals).** A first preferred product is a dairy supplement or formulated dairy product for consumption by infants or children to prevent development of obesity. A second preferred product is a **dietary supplement** for persons combating unwanted weight gain or obesity. Also featured are methods of formulating these dietary products (abstract only).

Corkey et al. teach a combination of MCFA and DHA Reduces Lipogenesis, Lipid Storage, and Secretion from Liver Cells (Please see example 12, paragraphs 121 and 122).

Corkey et al. teach dietary supplements and products aimed at preventing obesity, reducing fat mass, and/or reducing serum TGs (in particular, serum TGs associated with traditional MCT diets) [0006].



Corkey et al. teach [...]Because the .omega.-3 long chain fatty acids (EPA:DHA) have been shown to efficiently inhibit fatty acid synthesis, it is proposed that mixing MCFA with a small portion of EPA and DHA will synergize the positive effects of both types of fatty acids in reducing fat storage in adipose tissue and fat product [0121].

Corkey et al. teach a dietary regimen to be incorporated concomitantly with the said weight-reduction formulation. The present invention features dietary supplements and products aimed at preventing obesity, reducing fat mass, and/or reducing serum TGs (in particular, serum TGs associated with traditional MCT diets) [0006]; [0034].

Corkey et al. teach a triglyceride form of the formulation. A glyceride is an ester of glycerol (1, 2, 3-propanetriol) with acyl radicals of fatty acids and is also known as an acylglycerol. If only one position of the glycerol molecule is esterified with a fatty acid, a "monoglyceride" is produced; if two positions are esterified, a "diglyceride" is produced; and if all three positions of the glycerol are esterified with fatty acid a "triglyceride" or "triacylglycerol" is produced. A glyceride is called "simple" if all esterified positions contain the same fatty acid; or "mixed" if different fatty acids are involved. The carbons of the glycerol backbone are designated sn-1, sn-2 and sn-3, with sn-2 being in the middle and sn-1 and sn-3 being the ends of the glycerol [0033].

Thus, it would be *prima facie* obvious to one of ordinary skill in the art to at once recognize a reasonable expectation of success via the incorporating together the methods and teachings of O'Connor et al., Breivik et al, and Corkey et al. Determining the scope and contents of the prior art in view of the immediate references *supra* has been reasonably assessed.

Consummately, the Breivik et al. reference teaches the current invention. The specificities drawn to a particular target population suffering from specific risks and disorders associated with cardiovascular diseases in need of such formulations are adequately supported and taught by Corkey et al. O' Connor et al. teach a higher percent concentration of DHA to EPA in obviousness over the claimed invention. Thus, in view of O'Connor et al., whether recognized or not, a method for at least treating obesity, overweight condition, weight reduction, etc. is fully contemplated and supported by O'Connor et al.

Accordingly, the level of ordinary skill in the pertinent art suggests well-known and well-established protocols which are sufficiently described, defined, and explained in the references above. As a result, the inventive objective of current invention is made obvious. In consideration of the objective evidence present in the current application, it would have been *prima facie* obvious to combine the references together in obviousness over the claimed invention.

In view of the differences, it would have been *prima facie* obvious to one of ordinary skill in the art at the time the claimed invention was made to employ the fatty acid composition for treating persons with obesity because it is well-established in the art that the administration of such supplements aid in the treatment of weight control. Corkey et al. teach ratios of medium chain fatty acids and .omega.-polyunsaturated fatty acids. Further, the said reference teaches consumption of these dietary products [which] can contribute to the prevention of obesity in developing individuals and can contribute to a reduction in body fat mass in individuals who are trying to loose weight or reduce body fat mass (e.g., obese individuals). Accordingly, the reference of Corkey et al. reads on dietary formulations of the said fatty acids.

Similarly, it would have been obvious to one of ordinary skill in the art at the time the claimed invention was made to make a dietary composition either in the form of a snack or emulsion. Accordingly, the reference of Corkey et al. reads on dietary formulations of which the said fatty acids are comprised.

### ***Conclusion***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to TIMOTHY BETTON whose telephone number is (571)272-9922. The Examiner can normally be reached from Monday to Friday from 9am-5pm.

If attempts to reach the examiner by telephone are unsuccessful, the Examiner's supervisor, Sreeni Padmanabhan can be reached on (571) 272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

TEB

/SREENI PADMANABHAN/

Art Unit: 1627

Supervisory Patent Examiner, Art Unit 1627